BioSpace News Archive

Certain changes in a person’s heart and breathing rates could precede symptoms of COVID-19, an increasing number of studies suggests. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005184/en/ Purdue University researchers are helping to develop physIQ software that could indicate that a person should get tested for COVID-19 by detecting s

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced that the Mino-Lok Clinical Trial Material at each of the clinical sites has been replaced with registration batch product.

Newlab was honored in Fast Company’s Innovation by Design Awards for 2020 in the Design Company of the Year category

A new AI algorithm can identify when medical images are likely to be difficult for either a radiologist or AI to make an effective diagnosis.

The AAOS Shoulder & Elbow Registry recently received the Shoulder Arthroplasty Predictive Model, a tool designed to help surgeons predict post-operative shoulder arthroplasty outcomes, from Campbell Clinic Orthopaedics, a leader in musculoskeletal care and sports medicine.

American Regent, Inc. announces the introduction of Tralement™ (trace elements injection 4*, USP), the first and only FDA-approved multi-trace element injection.1 TralementTM is indicated in adult and pediatric patients weighing at least 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated

Updated COVID-19 case projections and county-level testing positivity rates released by PolicyLab at Children’s Hospital of Philadelphia show transmission risk has rapidly increased across much of the northern U.S., including the Pacific Northwest and Midwest, with increasing risk now moving into New York and other parts of the Northeast.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Paul G. Thomas has been appointed to its Board of Directors, effective September 30, 2020.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a company whose mission is to deliver innovative therapies that improve the lives of people with cancer, today announced that effective January 1, 2021, Mark Velleca, M.D. Ph.D., will transition to the role of senior advisor and continue to serve as a member of the G1 Board of Directors.

Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems